“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader
“How we live the first half of our lives really influences our freedom for morbidity and mortality the second half of our lives.” —Erin Michos
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?
Ultimately, the long-term benefits of lowering apoB through a one-time treatment may make this not only a viable future option, but potentially an intervention that could change preventive cardiovascular medicine.
This audio clip is from episode #48 with Matthew Walker, Ph.D., on sleep – Part II of III: Heart disease, cancer,…